Optimisation of steatotic donor livers in the era of machine perfusion

  • Research type

    Research Study

  • Full title

    High-risk steatotic donor livers in the era of normothermic machine perfusion: Application of novels therapies to achieve transplantability criteria

  • IRAS ID

    280477

  • Contact name

    Peter Friend

  • Contact email

    peter.friend@nds.ox.ac.uk

  • Sponsor organisation

    University of Oxford / Clinical Trials and Research Governance

  • Duration of Study in the UK

    2 years, 4 months, 1 days

  • Research summary

    A third of donated livers cannot be used for transplants due to the presence of fat within the liver cells (known as non-alcoholic fatty liver disease, NAFLD). Transplanting a fatty liver carries a greater risk to the patient compared to a normal liver as these livers do not tolerate conventional ice-box storage before transplantation.

    Our preliminary experiments point to an innovative defatting strategy for treatment of fatty human livers that were declined for transplantation. These livers were preserved on a machine in very similar conditions to those in the body (termed normothermic preservation). We added a combination of currently available drugs to release fat from liver cells, and we then removed the fat using a filter. This reduced the amount of fat in the liver and improved its function.

    However, evidence suggests that other key pathways may further enhance the success of these defatting strategies, in particular, pathways associated with oxygen sensing that are regulated by hypoxia inducible factors (HIFs). HIFs are activated in low oxygen environments and have both a protective and deleterious effect in the progression of NAFLD. Evidence from pre-clinical experiments suggests that HIF expression can be selectively modulated using pharmacological agents thereby providing therapeutic targets for NAFLD.

    We will initially investigate the effect of the defatting strategies on HIF expression within the liver using samples from our preliminary study. This will inform the basis our main study where we anticipate that the selective pharmacological modulation of HIF pathway during normothermic liver preservation will improve functional outcomes.

  • REC name

    London - Riverside Research Ethics Committee

  • REC reference

    20/PR/0111

  • Date of REC Opinion

    2 Jul 2020

  • REC opinion

    Favourable Opinion